DDrare: Database of Drug Development for Rare Diseases

Searched query = "Idiopathic multicentric castleman disease", "Castleman disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Best Supportive Care (BSC); Bevacizumab; Bortezomib; CNTO 328; CNTO328; CX-4945 oral formulation; Cetuximab; Chimeric murine human anti-IL-6 monoclonal antibody; Cyclophosphamide; Dexamethason; Doxorubicin; Doxorubicin Hydrochloride; Etoposide; Filgrastim; Filgrastim (G-CSF); G-CSF; Hyaluronidase; Interferon-alpha; Liposomal Doxorubicin; Methotrexate; Nelfinavir; Other: Laboratory Biomarker Analysis; Other: Observation Only; Other: Pharmacological Study; Pomalidomide; Prednisone; Rituximab; Rituximab or Rituximab Hyaluronidase Human; RoActemra; SILTUXIMAB; Siltuximab; Sirolimus; Suramin; Temsirolimus; Thalidomide; Thalidomide, cyclophosphamide and prednisone; Tocilizumab; Tocilizumab [RoActemra/Actemra]; Valganciclovir; Valganciclovir (VGC); Valproic Acid; Valproic acid; Vincristine; Zidovudine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01441063 (ClinicalTrials.gov)	September 13, 2011	24/9/2011	Tocilizumab for KSHV-Associated Multicentric Castleman Disease	Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease	Castleman Disease;Multicentric Castleman Disease;Giant Lymph Node Hyperplasia	Drug: Zidovudine;Drug: Tocilizumab;Drug: Valganciclovir (VGC)	National Cancer Institute (NCI)	NULL	Completed	18 Years	N/A	All	8	Phase 2	United States
2	NCT00092222 (ClinicalTrials.gov)	October 28, 2004	21/9/2004	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity	Lymphoproliferative Disorder;HHV-8;Malignancy;HIV	Drug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin;Drug: Bortezomib;Drug: Valganciclovir;Drug: Doxorubicin;Drug: Vincristine;Drug: Cyclophosphamide;Drug: Filgrastim (G-CSF);Drug: Prednisone;Drug: Sirolimus;Other: Observation Only	National Cancer Institute (NCI)	NULL	Recruiting	12 Years	N/A	All	72	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01441063
(ClinicalTrials.gov)

September 13, 2011

24/9/2011

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease

Castleman Disease;Multicentric Castleman Disease;Giant Lymph Node Hyperplasia

Drug: Zidovudine;Drug: Tocilizumab;Drug: Valganciclovir (VGC)

National Cancer Institute (NCI)

NULL

Completed

18 Years

N/A

All

Phase 2

United States

NCT00092222
(ClinicalTrials.gov)

October 28, 2004

21/9/2004

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity

Lymphoproliferative Disorder;HHV-8;Malignancy;HIV

Drug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin;Drug: Bortezomib;Drug: Valganciclovir;Drug: Doxorubicin;Drug: Vincristine;Drug: Cyclophosphamide;Drug: Filgrastim (G-CSF);Drug: Prednisone;Drug: Sirolimus;Other: Observation Only

National Cancer Institute (NCI)

NULL

Recruiting

12 Years

N/A

All

Phase 2

United States